Developer docs
API playgroundTry for free, no card

Search company profiles

TheraPsil

Full company profile

uuid0023ndy

Namestring
TheraPsil
Legal namestring
TheraPsil
Websiteurl
therapsil.ca
Company typeenum
Private
Founded yearint
2019
Descriptiontext

TheraPsil is a Canadian non-profit founded in 2019 on Vancouver Island, headquartered in Victoria, British Columbia. The organization trains healthcare professionals in psychedelic-assisted psychotherapy and operates patient-support and advocacy programs aimed at expanding legal access to psilocybin in Canada. Its product set is curriculum-based rather than software-based: Psilocybin-Assisted Therapy Training, MDMA-Assisted Therapy Training, Prescriber Courses for psilocybin and MDMA, Psychedelic First Aid and Advanced Seminars, On-Demand self-paced modules, and a supervised Experiential Psilocybin Training component. Adjacent offerings include patient navigation services (therapist and co-sitter directories), the PsilWell Clinical Trial for psilocybin outcomes research, recurring masterclass events with leading researchers, grassroots legal advocacy (including support for Thomas' Bill), and a merchandise storefront. The organization's underlying technology consists of online training portals, a membership platform, and clinical trial management infrastructure — there is no proprietary AI, software-as-a-service product, or app.

Short descriptiontext

TheraPsil is a Canadian non-profit founded in 2019 that trains healthcare professionals in psychedelic-assisted therapy, supports patients seeking legal psilocybin access, runs the PsilWell clinical trial, and advocates for psychedelic regulatory reform in Canada.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
psychedelic therapy training, psilocybin-assisted therapy, MDMA-assisted therapy, mental health training, clinical trial research
Industry2 codes
PRIMARYEDAAALAD
Behavioral Health & Counseling (Social Work, Psychology, Substance Use CE)
Education/Adult & Continuing Education/Professional Licensure & Continuing Professional Education (CE/CPE)
SECONDARYHLAFACAN
Peer Support, Recovery Coaching & Sober Living Services
Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment
NAICS code3 codes
  • Educational Support Services61171
  • Outpatient Mental Health and Substance Abuse Centers621420
  • Other Individual and Family Services624190
SIC code2 codes
  • Services-Educational Services8200
  • Services-Social Services8300
Product category
Psychedelic-Assisted Therapy Training
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Training Program Fees
TypeProfessional Services
Description

Revenue from psychedelic therapy training programs for healthcare professionals including Psilocybin-Assisted Therapy, MDMA-Assisted Therapy, and Prescriber courses offered in-person and online.

therapsil.ca
2Membership Fees
TypeSubscription Recurring
Description

Monthly or annual membership subscriptions providing access to newsletters, webinars, bonus training resources, hub directories, exclusive events, and advocacy access.

therapsil.ca
3Merchandise Sales
TypeHardware Sales
Description

Sale of branded merchandise including the 'Right to Try Organic Cotton Tote' at $26 per unit.

therapsil.ca
4Donations and Advocacy Support
TypeAffiliate Referral
Description

Donations funding legal advocacy, public education, and direct patient support for expanding compassionate psilocybin access in Canada.

therapsil.ca
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details3 tiers
1Masterclass General Admission
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$249 general admission for the full-day masterclass event including lecture, Q&A, panel discussion, lunch, and meditations.

therapsil.ca
2Masterclass Member Rate
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$199 for TheraPsil members. Student and sliding scale rates available upon request via email.

therapsil.ca
3Right to Try Organic Cotton Tote
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$26 per tote bag. Features 'Right to Try' text with TheraPsil Heart Logo. Made from 100% certified organic cotton.

therapsil.ca
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

TheraPsil delivers professional training programs in psychedelic-assisted psychotherapy (psilocybin and MDMA) to healthcare professionals, delivered in small supervised cohorts in-person in Victoria/Toronto and online. It also provides patient support and navigation services connecting patients with trained therapists, operates the PsilWell clinical trial, maintains therapist and co-sitter directories, runs a subscription membership program, hosts masterclass events, and conducts grassroots advocacy for legal psilocybin access in Canada.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 80% of participants experience significant relief from depression and anxiety after psilocybin therapy in clinical trials
Product overview1 text field

TheraPsil is a non-profit training and advocacy organization (not a technology product company) offering psychedelic-assisted therapy education programs for healthcare professionals. The core offering consists of multiple training programs including Psilocybin-Assisted Therapy Training, MDMA-Assisted Therapy Training, Prescriber Courses, and Experiential Training components. Additional services include patient support programs (therapist and co-sitter directories), the PsilWell clinical trial research program, advocacy efforts for legal access, membership benefits, educational masterclass events, and merchandise. The organization does not offer a software platform, SaaS product, or technology solution.

Product and service13 records
1Psilocybin-Assisted Therapy Training
CategoryTraining Program
Description

Comprehensive training program for healthcare professionals covering psilocybin-assisted psychotherapy techniques, including fundamentals, in-person and online formats, and supervision components leading to supervised experiential training.

2MDMA-Assisted Therapy Training
CategoryTraining Program
Description

Training program for healthcare professionals on MDMA-assisted psychotherapy protocols and clinical practices.

3Prescriber Courses (Psilocybin & MDMA)
CategoryTraining Program
Description

Specialized courses for prescribing clinicians on protocols for psilocybin and MDMA therapies.

4Psychedelic First Aid & Advanced Seminars
CategoryTraining Program
Description

Advanced seminars covering psychedelic first aid and practitioner preparedness.

5Experiential Psilocybin Training
CategoryTraining Program
Description

Supervised hands-on experiential training allowing participants to experience psilocybin-assisted therapy under monitored conditions.

6PsilWell Clinical Trial
CategoryResearch Program
Description

Clinical trial program investigating psilocybin therapy outcomes in patient populations.

7Patient Support Services
CategorySupport Service
Description

Services connecting qualified individuals to trained psychedelic therapy providers, including application support for legal access.

8Masterclass Events
CategoryEvents
Description

Educational full-day masterclasses featuring leading voices in psychedelic research, with featured speakers and panel discussions.

9Advocacy & Legal Access Program
CategoryAdvocacy
Description

Grassroots advocacy efforts for psychedelic regulations, legal challenges, and patient access to psilocybin therapy in Canada.

10Membership Program
CategoryMembership
Description

Recurring monthly or annual membership providing access to newsletters, webinars, training portals, directories, exclusive events, and community connections.

11Therapist Directory
CategoryDirectory
Description

Directory of trained psychedelic therapy practitioners available for patient referrals.

12Co-Sitter Directory
CategoryDirectory
Description

Directory of trained co-sitters for psychedelic-assisted therapy sessions.

13Right to Try Organic Cotton Tote
CategoryMerchandise
Description

Branded organic cotton tote bag featuring 'Right to Try' messaging to support psychedelic advocacy. Priced at $26 per unit.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership25 partners
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem. Organizations in the ecosystem help shape the future of psychedelic care alongside TheraPsil.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

6CRIO
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

therapsil.ca
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

8Drug Science
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

therapsil.ca
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

12Global Psychedelics Week
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

therapsil.ca
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

15Nikean
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

therapsil.ca
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

21PsyGaia
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

therapsil.ca
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

23Psilocybin San Francisco
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

therapsil.ca
Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Strategic tierMinorTypeOthers
Description

Listed as part of TheraPsil's broader psychedelic ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Provides psychedelic-assisted therapy training programs for clinicians, including ketamine and psilocybin tracks. Closely comparable to TheraPsil's training portfolio, curriculum structure, and target customer base of healthcare professionals.

TypeBroad incumbent
Description

Publicly listed clinical-stage psychedelic therapy company running psilocybin trials and developing proprietary COMP360 protocols. Larger, capital-backed player with overlapping patient, clinician, and policy ecosystem compared to TheraPsil.

TypeEmerging player
Description

Canadian psychedelic-assisted therapy clinic network with therapist directories and patient services. Comparable to TheraPsil's patient-support and therapist-directory offering, with overlap in clinician community and listed ecosystem partnership.

TypeOthers
Description

Canadian natural psychedelic drug development company and listed TheraPsil ecosystem partner. Adjacent as a drug-development supplier rather than training peer, but provides supply chain context for TheraPsil's clinical work.

TypeBroad incumbent
Description

Foundational psychedelic research and training organization sponsoring MDMA-assisted therapy protocols globally. Operates broader portfolio (clinical trials, public policy, training) but competes directly with TheraPsil on therapist training and patient access advocacy.

TypeBroad incumbent
Description

University-based program offering certificate-level psychedelic therapy training for clinicians. Comparable to TheraPsil's training mission, with greater institutional backing but U.S. focus rather than Canadian.

TypeRegional player
Description

New Zealand-based psychedelic therapy training organization listed as part of TheraPsil's ecosystem. Directly comparable in training mission, with primary geographic focus on Aotearoa New Zealand where TheraPsil is also expanding.

TypeDirect peer
Description

Offers continuing-education psychedelic-assisted therapy training for licensed clinicians. Closely comparable product offering and target audience to TheraPsil's professional training programs.

TypeDirect peer
Description

Canadian national organization advancing psychedelic therapy and policy reform. Directly comparable advocacy mission to TheraPsil, listed as an ecosystem ally with overlapping member base.

TypeDirect peer
Description

Canadian arm of the Multidisciplinary Association for Psychedelic Studies, focused on MDMA-assisted therapy training, research, and policy advocacy. Directly comparable to TheraPsil as a Canadian psychedelic healthcare training and advocacy organization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TheraPsil

Psychedelic-Assisted Therapy Trainingtherapsil.ca

TheraPsil is a Canadian non-profit founded in 2019 that trains healthcare professionals in psychedelic-assisted therapy, supports patients seeking legal psilocybin access, runs the PsilWell clinical trial, and advocates for psychedelic regulatory reform in Canada.

What TheraPsil does

TheraPsil is a Canadian non-profit founded in 2019 on Vancouver Island, headquartered in Victoria, British Columbia. The organization trains healthcare professionals in psychedelic-assisted psychotherapy and operates patient-support and advocacy programs aimed at expanding legal access to psilocybin in Canada. Its product set is curriculum-based rather than software-based: Psilocybin-Assisted Therapy Training, MDMA-Assisted Therapy Training, Prescriber Courses for psilocybin and MDMA, Psychedelic First Aid and Advanced Seminars, On-Demand self-paced modules, and a supervised Experiential Psilocybin Training component. Adjacent offerings include patient navigation services (therapist and co-sitter directories), the PsilWell Clinical Trial for psilocybin outcomes research, recurring masterclass events with leading researchers, grassroots legal advocacy (including support for Thomas' Bill), and a merchandise storefront. The organization's underlying technology consists of online training portals, a membership platform, and clinical trial management infrastructure — there is no proprietary AI, software-as-a-service product, or app.

TheraPsil firmographics

Firmographics
Name
TheraPsil
Legal name
TheraPsil
Website
https://therapsil.ca
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
TheraPsil is a Canadian non-profit founded in 2019 that trains healthcare professionals in psychedelic-assisted therapy, supports patients seeking legal psilocybin access, runs the PsilWell clinical trial, and advocates for psychedelic regulatory reform in Canada.
Ownership category
akta.pro rank

TheraPsil industry classification

Industry
Product category
Psychedelic-Assisted Therapy Training
NAICS
Educational Support Services (61171), Outpatient Mental Health and Substance Abuse Centers (621420), Other Individual and Family Services (624190)
SIC
Services-Educational Services (8200), Services-Social Services (8300)
akta.pro industry
PRIMARYEDAAALAD
Behavioral Health & Counseling (Social Work, Psychology, Substance Use CE)
Education/Adult & Continuing Education/Professional Licensure & Continuing Professional Education (CE/CPE)
SECONDARYHLAFACAN
Peer Support, Recovery Coaching & Sober Living Services
Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment

Keywords

  • Psychedelic therapy training
  • Psilocybin-assisted therapy
  • MDMA-assisted therapy
  • Mental health training
  • Clinical trial research

Where TheraPsil is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

TheraPsil business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Training Program Fees: Revenue from psychedelic therapy training programs for healthcare professionals including Psilocybin-Assisted Therapy, MDMA-Assisted Therapy, and Prescriber courses offered in-person and online.
  2. Membership Fees: Monthly or annual membership subscriptions providing access to newsletters, webinars, bonus training resources, hub directories, exclusive events, and advocacy access.
  3. Merchandise Sales: Sale of branded merchandise including the 'Right to Try Organic Cotton Tote' at $26 per unit.
  4. Donations and Advocacy Support: Donations funding legal advocacy, public education, and direct patient support for expanding compassionate psilocybin access in Canada.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goMasterclass General Admission
One time/ perpetual licensePay-as-you-goMasterclass Member Rate
Unit PricingPay-as-you-goRight to Try Organic Cotton Tote

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

TheraPsil product offering

Product offering

Core offering

TheraPsil delivers professional training programs in psychedelic-assisted psychotherapy (psilocybin and MDMA) to healthcare professionals, delivered in small supervised cohorts in-person in Victoria/Toronto and online. It also provides patient support and navigation services connecting patients with trained therapists, operates the PsilWell clinical trial, maintains therapist and co-sitter directories, runs a subscription membership program, hosts masterclass events, and conducts grassroots advocacy for legal psilocybin access in Canada.

Product overview

TheraPsil is a non-profit training and advocacy organization (not a technology product company) offering psychedelic-assisted therapy education programs for healthcare professionals. The core offering consists of multiple training programs including Psilocybin-Assisted Therapy Training, MDMA-Assisted Therapy Training, Prescriber Courses, and Experiential Training components. Additional services include patient support programs (therapist and co-sitter directories), the PsilWell clinical trial research program, advocacy efforts for legal access, membership benefits, educational masterclass events, and merchandise. The organization does not offer a software platform, SaaS product, or technology solution.

Differentiator

Problem solved

Functional benefit

Products and services

  • Psilocybin-Assisted Therapy Training Comprehensive training program for healthcare professionals covering psilocybin-assisted psychotherapy techniques, including fundamentals, in-person and online formats, and supervision components leading to supervised experiential training.
  • MDMA-Assisted Therapy Training Training program for healthcare professionals on MDMA-assisted psychotherapy protocols and clinical practices.
  • Prescriber Courses (Psilocybin & MDMA) Specialized courses for prescribing clinicians on protocols for psilocybin and MDMA therapies.
  • Psychedelic First Aid & Advanced Seminars Advanced seminars covering psychedelic first aid and practitioner preparedness.
  • Experiential Psilocybin Training Supervised hands-on experiential training allowing participants to experience psilocybin-assisted therapy under monitored conditions.
  • PsilWell Clinical Trial Clinical trial program investigating psilocybin therapy outcomes in patient populations.
  • Patient Support Services Services connecting qualified individuals to trained psychedelic therapy providers, including application support for legal access.
  • Masterclass Events Educational full-day masterclasses featuring leading voices in psychedelic research, with featured speakers and panel discussions.
  • Advocacy & Legal Access Program Grassroots advocacy efforts for psychedelic regulations, legal challenges, and patient access to psilocybin therapy in Canada.
  • Membership Program Recurring monthly or annual membership providing access to newsletters, webinars, training portals, directories, exclusive events, and community connections.
  • Therapist Directory Directory of trained psychedelic therapy practitioners available for patient referrals.
  • Co-Sitter Directory Directory of trained co-sitters for psychedelic-assisted therapy sessions.
  • Right to Try Organic Cotton Tote Branded organic cotton tote bag featuring 'Right to Try' messaging to support psychedelic advocacy. Priced at $26 per unit.

Quantifiable outcome

  • 80% of participants experience significant relief from depression and anxiety after psilocybin therapy in clinical trials

Companies that use TheraPsil

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

TheraPsil technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

TheraPsil partnerships and signals

Strategic signal

Partnerships

25 partnerships are on record, tiered minor.

  • ACER IntegrationminorOthersListed as part of TheraPsil's broader psychedelic ecosystem. Organizations in the ecosystem help shape the future of psychedelic care alongside TheraPsil.
  • Apex LabsminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • BlossomminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • ChacrunaminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • ClusterbustersminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • CRIOminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Dr. Bronner'sminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Drug ScienceminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Enhanced Therapy InstituteminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Filament HealthminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • First SessionminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Global Psychedelics WeekminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Heroic Hearts CanadaminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • MAPS CanadaminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • NikeanminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • OPISminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Optimi HealthminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Psychedelic Association of CanadaminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Psychedelics & Pain AssociationminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • PsygenminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • PsyGaiaminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Psychedelic Training NZminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • Psilocybin San FranciscominorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • REMAP TherapeuticsminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.
  • SABI MindminorOthersListed as part of TheraPsil's broader psychedelic ecosystem.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

TheraPsil competitors and assessment

Company assessment

Direct peers

  • Fluence: Provides psychedelic-assisted therapy training programs for clinicians, including ketamine and psilocybin tracks. Closely comparable to TheraPsil's training portfolio, curriculum structure, and target customer base of healthcare professionals.
  • Naropa University Psychedelic Training Program: Offers continuing-education psychedelic-assisted therapy training for licensed clinicians. Closely comparable product offering and target audience to TheraPsil's professional training programs.
  • Psychedelic Association of Canada: Canadian national organization advancing psychedelic therapy and policy reform. Directly comparable advocacy mission to TheraPsil, listed as an ecosystem ally with overlapping member base.
  • MAPS Canada: Canadian arm of the Multidisciplinary Association for Psychedelic Studies, focused on MDMA-assisted therapy training, research, and policy advocacy. Directly comparable to TheraPsil as a Canadian psychedelic healthcare training and advocacy organization.

Broad incumbents

  • Compass Pathways: Publicly listed clinical-stage psychedelic therapy company running psilocybin trials and developing proprietary COMP360 protocols. Larger, capital-backed player with overlapping patient, clinician, and policy ecosystem compared to TheraPsil.
  • Multidisciplinary Association for Psychedelic Studies (MAPS): Foundational psychedelic research and training organization sponsoring MDMA-assisted therapy protocols globally. Operates broader portfolio (clinical trials, public policy, training) but competes directly with TheraPsil on therapist training and patient access advocacy.
  • California Institute of Integral Studies (CIIS) Center for Psychedelic Therapies and Research: University-based program offering certificate-level psychedelic therapy training for clinicians. Comparable to TheraPsil's training mission, with greater institutional backing but U.S. focus rather than Canadian.

Emerging players

  • SABI Mind: Canadian psychedelic-assisted therapy clinic network with therapist directories and patient services. Comparable to TheraPsil's patient-support and therapist-directory offering, with overlap in clinician community and listed ecosystem partnership.

Others

  • Filament Health: Canadian natural psychedelic drug development company and listed TheraPsil ecosystem partner. Adjacent as a drug-development supplier rather than training peer, but provides supply chain context for TheraPsil's clinical work.

Regional players

  • Psychedelic Training NZ: New Zealand-based psychedelic therapy training organization listed as part of TheraPsil's ecosystem. Directly comparable in training mission, with primary geographic focus on Aotearoa New Zealand where TheraPsil is also expanding.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

TheraPsil social profiles

Digital presence

TheraPsil financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TheraPsil leadership team

Management profile

Number of profiles

Profiles6 records

TheraPsil funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TheraPsil M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TheraPsil

What does TheraPsil do?

TheraPsil delivers professional training programs in psychedelic-assisted psychotherapy (psilocybin and MDMA) to healthcare professionals, delivered in small supervised cohorts in-person in Victoria/Toronto and online. It also provides patient support and navigation services connecting patients with trained therapists, operates the PsilWell clinical trial, maintains therapist and co-sitter directories, runs a subscription membership program, hosts masterclass events, and conducts grassroots advocacy for legal psilocybin access in Canada.

Is TheraPsil a public or private company?

TheraPsil is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was TheraPsil founded?

TheraPsil was founded in 2019. It employs 11 to 50 people.

Where is TheraPsil based?

TheraPsil is headquartered in Vancouver, Canada, in the North America region.

How does TheraPsil make money?

Four revenue lines are on record. Training Program Fees are the primary driver. The others are membership Fees, merchandise Sales and donations and Advocacy Support.

Who are TheraPsil's main competitors?

Direct peers on record are Fluence, Naropa University Psychedelic Training Program, Psychedelic Association of Canada and MAPS Canada. Broad incumbents are Compass Pathways, Multidisciplinary Association for Psychedelic Studies (MAPS) and California Institute of Integral Studies (CIIS) Center for Psychedelic Therapies and Research. SABI Mind is listed as an emerging player. Filament Health is listed as an others. Psychedelic Training NZ is listed as a regional player.

Does TheraPsil have an API?

No public API is recorded for TheraPsil.

What industry is TheraPsil in?

TheraPsil's product category is Psychedelic-Assisted Therapy Training. Its primary akta.pro industry code is EDAAALAD, Behavioral Health & Counseling (Social Work, Psychology, Substance Use CE), with a secondary code of HLAFACAN, Peer Support, Recovery Coaching & Sober Living Services. Its NAICS code is 61171 and its SIC code is 8200.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireLucy Scientific Discovery Inc. Accelerates Psilocybin Access and Product Launch through a Strategic Partnership with TheraPsilLucy Scientific Discovery Inc. announced a partnership with TheraPsil to advance medical psilocybin access and research in Canada. The collaboration aims to provide compassionate care and collect real-world data, while Lucy will introduce natural psilocybin products to the Canadian market. The partnership is expected to build brand recognition and attract global attention.GlobeNewswireCore One Labs Applauds TheraPsil on Its Submission to Health CanadaCore One Labs applauded TheraPsil's submission to Health Canada to end the 50-year ban on psilocybin mushrooms. The proposal covers supply chain, quality control, and patient registration, similar to medicinal cannabis. Core One also retained Promethean for investor relations and marketing for $935,000.GlobeNewswireOptimi Health Supports Patient-Focused Psilocybin Advocacy by TheraPsilOptimi Health announced it initiated corporate support as a Core Spore Supporter for TheraPsil, donating and advocating for psilocybin-assisted psychotherapy access in Canada. TheraPsil has facilitated 31 patients' access to exemptions since 2020, and Optimi's chairman said the company aims to bring consistent dosing to natural psilocybin upon receiving a dealer's license.PR NewswireNew Wave Holdings Congratulates TheraPsil's Advocacy to Bring Psilocybin Therapy to Palliative Care for Canadian PatientsNew Wave Holdings Corp. announced that 17 healthcare professionals associated with TheraPsil, a non-profit coalition, have been approved by Canadian Federal Health Minister Patty Hajdu to possess and use psilocybin for professional training in psychedelic therapy, granted through exemptions to section 56(1) of the Canadian Drugs & Substances Act. The approvals follow 166 days of advocacy by TheraPsil, which has been working since 2019 to establish compassionate access to psilocybin therapy for Canadians in palliative care. New Wave Holdings, an investment issuer focused on the psychedelic sector, sponsored TheraPsil's advocacy efforts and expressed optimism about the therapeutic potential of psychedelic medicine.GlobeNewswirePalliative Canadians endure punishing waits while Health Minister delays approval of Psilocybin mushrooms; TheraPsil expands effort to OntarioTheraPsil, a BC-based coalition, expanded its program to invite Ontario patients to support Section 56 applications for psilocybin-assisted therapy. At least four dying Canadians have applied, including Thomas Hartle and Laurie Brooks, who cite end-of-life distress. The coalition urges Health Minister Patty Hajdu to respond to their requests.GlobeNewswireTheraPsil launches program to assist patients in accessingTheraPsil, a BC-based non-profit, launched a program to help terminally-ill British Columbians access psilocybin-assisted psychotherapy, which is illegal in Canada. The program assists qualified patients in filing for a federal exemption to the Minister of Health. It also includes public education, professional training, and research components.PR NewswireNew Wave Holdings Sponsors Non-Profit Coalition, Therapsil, to Launch a Medical Psilocybin Access Project for Canadians in Palliative CareNew Wave Holdings Corp. announced it is sponsoring TheraPsil, a British Columbia-based non-profit coalition, to support their medical psilocybin access project for Canadians in palliative care experiencing psychological distress. The sponsorship will enable TheraPsil to dedicate more time and resources toward obtaining legal access to psilocybin-assisted therapy for terminally ill patients. New Wave Holdings is an investment issuer focused on the psychedelic and esports sectors, with Dr. Bruce Tobin serving as founder of TheraPsil and Trumbull Fisher as President of New Wave.GlobeNewswireREPEAT - Champignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patients and Health ProfessionalsChampignon Brands is sponsoring TheraPsil, a BC-based coalition seeking legal psilocybin access for palliative cancer patients. The coalition, founded in 2019, aims to establish safe, legal access, public education, professional training, and research. Champignon is also developing psilocybin-cannabidiol treatments for PTSD.GlobeNewswireChampignon Sponsors Non-profit Coalition, TheraPsil - Medical Psilocybin Access Project for Palliative Cancer Patients and Health ProfessionalsChampignon Brands Inc. announced sponsorship of TheraPsil, a BC-based coalition seeking legal psilocybin access for palliative cancer patients. The coalition aims to establish safe, legal access, public education, professional training, and research. Champignon is also developing psilocybin-cannabidiol treatments for PTSD.